Toxicity of oxyquinolines

Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.

Nature medicine·2026

Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.

The journal of prevention of Alzheimer's disease·2024

A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2024

Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer's Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project.

The journal of prevention of Alzheimer's disease·2024

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force.

The journal of prevention of Alzheimer's disease·2023

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.

The journal of prevention of Alzheimer's disease·2023

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Lancet (London, England)·2026

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Lancet (London, England)·2026

Advancing the relevance of clinical trials for older patients.

Lancet (London, England)·2026

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Lancet (London, England)·2026

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Lancet (London, England)·2026

Olfactomedin 2 Promotes Atherosclerosis by Eliciting Smooth Muscle Foam Cell Formation.

Arteriosclerosis, thrombosis, and vascular biology·2026

Neutral-cumulenic diazo (X[double bond, length as m-dash]C[double bond, length as m-dash]N2) compounds.

Chemical science·2026

Asymmetric radical type 1,2-aryloxy-phosphinolylation of vinylarenes catalyzed by chiral vanadyl complexes.

Communications chemistry·2026

A Postsynthetic Strategy for Oligonucleotides Containing 2-Fluoro-adenine and Isoguanine Nucleobases.

Organic letters·2026

NO and NO2 reactions with oxygenated peroxy radicals lead to indistinguishable product compositions: computational insights from cyclohexene oxidation in presence of NO x.

Environmental science: atmospheres·2026

Formation of Hydroxylated-Benzoyl-Benzofuranones Following the Exposure of Quercetin and Kaempferol to aNitrite-Containing Acidic Medium.

Molecules (Basel, Switzerland)·2026

Related Experiment Videos

Toxicity of oxyquinolines

Related Concept Videos

Human embryonic stem cell-derived dopaminergic cells for Parkinson's disease: a phase 1/2 open-label trial.

Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.

A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer's Disease.

Validation, Deployment, and Real-World Implementation of a Modular Toolbox for Alzheimer's Disease Detection and Dementia Risk Reduction: The AD-RIDDLE Project.

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force.

Investigating Partially Discordant Results in Phase 3 Studies of Aducanumab.

1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

Advancing the relevance of clinical trials for older patients.

Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

Olfactomedin 2 Promotes Atherosclerosis by Eliciting Smooth Muscle Foam Cell Formation.

Neutral-cumulenic diazo (X[double bond, length as m-dash]C[double bond, length as m-dash]N<sub>2</sub>) compounds.

Asymmetric radical type 1,2-aryloxy-phosphinolylation of vinylarenes catalyzed by chiral vanadyl complexes.

A Postsynthetic Strategy for Oligonucleotides Containing 2-Fluoro-adenine and Isoguanine Nucleobases.

NO and NO<sub>2</sub> reactions with oxygenated peroxy radicals lead to indistinguishable product compositions: computational insights from cyclohexene oxidation in presence of NO <sub><i>x</i></sub>.

Formation of Hydroxylated-Benzoyl-Benzofuranones Following the Exposure of Quercetin and Kaempferol to aNitrite-Containing Acidic Medium.

Related Experiment Videos

Toxicity of oxyquinolines

Related Concept Videos

Related Articles